Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787135 | 0.87 | LMNA (0.32) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL22787137 | 0.87 | LMNA (0.34) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL22787187 | 0.87 | KMT2A (0.35) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL22787183 | 0.84 | KMT2A (0.32) | LMNAHTT | |
| SCHEMBL22787189 | 0.84 | — | — | |
| SCHEMBL22773545 | 0.83 | LMNA (0.35) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL22773547 | 0.83 | LMNA (0.35) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL22787131 | 0.83 | LMNA (0.35) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL17231868 | 0.81 | MAPT (0.42) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL12679101 | 0.81 | MAPT (0.42) | LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-08-25 | — | — | US | disclosed |
| WO-2020248065-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | AADAC, ACSL3, ACSL1 | LMNA 845/4885HTT 1360/4885SMN1; SMN2 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.